Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Xeroderma pigmentosum.Orphanet J Rare Dis. 2011; 6: 70
- Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature.Eur J Canc. 2017; 83: 99-102
- Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.Eur J Canc. 2017; 77: 84-87
- Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.Cold Spring Harb Mol Case Stud. 2019; 5
- Angiosarcoma arising on the scalp in a Korean patient with xeroderma pigmentosum variant type.Photodermatol Photoimmunol Photomed. 2018; 34: 343-346
- Angiosarcoma of the head and neck associated with xeroderma pigmentosum variant.Br J Dermatol. 1999; 141: 166-167
- A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401).Lancet Oncol. 2018; 19: 416-426
- Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.J Clin Invest. 2016; 126: 2334-2340
- Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.Pediatr Dermatol. 2018; 35: e334-e336